Harrihar A Pershadsingh

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome
    Harrihar A Pershadsingh
    Bethesda Pharmaceuticals, Inc, 404 Windsor Park Drive, Bakersfield, California 93311, USA
    Expert Opin Investig Drugs 16:291-302. 2007
  2. pmc PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies
    Harrihar A Pershadsingh
    Department of Family Medicine, University of California, Irvine, CA 92797, USA
    PPAR Res 2008:164273. 2008
  3. pmc Endothelial function and urine albumin levels among asymptomatic Mexican-Americans and non-Hispanic whites
    Julius M Gardin
    Division of Cardiology, Department of Medicine, St, John Hospital and Medical Center, Detroit, MI 48236, USA
    Cardiovasc Ultrasound 6:43. 2008
  4. ncbi Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma
    Harrihar A Pershadsingh
    Department of Family Medicine, Kern Medical Center, Bakersfield, CA 93305, USA
    Int J Biochem Cell Biol 38:766-81. 2006
  5. ncbi Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient
    Harrihar A Pershadsingh
    Department of Family Medicine, Kern Medical Center, Bakersfield, CA 93305, and the Department of Family Medicine, University of California, Irvine, Irvine, CA, USA
    Skinmed 4:386-90. 2005
  6. ncbi Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand
    Melvin A Sarayba
    Department of Ophthalmology, University of California, 118 Med Surge I, Irvine, CA 92697 4375, USA
    Exp Eye Res 80:435-42. 2005
  7. ncbi Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone
    Nianning Qi
    Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    J Biol Chem 277:48501-7. 2002
  8. ncbi Alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases
    Meenakshi S Venkatraman
    Department Medicinal Chemistry, University of Mississippi, University, MS, USA
    Arch Dermatol Res 296:97-104. 2004
  9. ncbi Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
    James Varani
    University of Michigan Medical School, Department of Pathology, 1301 Catherine Road Box 0602, Ann Arbor, MI 48109, USA
    Expert Opin Investig Drugs 15:1453-68. 2006
  10. ncbi Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists
    Amar G Chittiboyina
    Laboratory for Applied Drug Design and Synthesis, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, 38677, USA
    J Med Chem 49:4072-84. 2006

Collaborators

  • Li Li
  • Stephen C Benson
  • Roy S Chuck
  • JAMES J VARANI
  • T W Kurtz
  • Douglas Feinstein
  • Michael T Heneka
  • M Pravenec
  • Mitchell A Avery
  • Amar Chittiboyina
  • Narasimharao Bhagavathula
  • Cassia S Mizuno
  • Amar G Chittiboyina
  • Christopher I Ho
  • Meenakshi S Venkatraman
  • Charles N Ellis
  • Julius M Gardin
  • Melvin A Sarayba
  • Kamalakar C Nerusu
  • Nianning Qi
  • Nathan D Wong
  • Renee L Bess
  • M Anne Spence
  • Zuhair Allebban
  • Sharon K Sklar
  • Prashant V Desai
  • Akshay Patny
  • Mitchell Avery
  • Kathryn E Osann
  • Paula M Sweet
  • Norman H Liu
  • Mahendranath Reddy
  • Anup J Patel
  • Tulaya Tungsiripat
  • Josef Meingassner
  • Ashish Lal
  • Nada A Abumrad
  • Ludmila Kazdova
  • Vladimir Kren
  • Vaclav Zidek
  • Vladimir Landa
  • Elizabeth St Lezin

Detail Information

Publications16

  1. ncbi Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome
    Harrihar A Pershadsingh
    Bethesda Pharmaceuticals, Inc, 404 Windsor Park Drive, Bakersfield, California 93311, USA
    Expert Opin Investig Drugs 16:291-302. 2007
    ..To a large extent, these findings can explain the observed beneficial metabolic effects of alpha-lipoic acid, supporting its potential application as a therapeutic agent for the treatment of the metabolic syndrome...
  2. pmc PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies
    Harrihar A Pershadsingh
    Department of Family Medicine, University of California, Irvine, CA 92797, USA
    PPAR Res 2008:164273. 2008
    ..Therefore, the TZDs and telmisartan, clinically approved antidiabetic and antihypertensive drugs, respectively, may be efficacious for treating and attenuating PDR and CNV humans. Clinical trials are needed to test these possibilities...
  3. pmc Endothelial function and urine albumin levels among asymptomatic Mexican-Americans and non-Hispanic whites
    Julius M Gardin
    Division of Cardiology, Department of Medicine, St, John Hospital and Medical Center, Detroit, MI 48236, USA
    Cardiovasc Ultrasound 6:43. 2008
    ..Our aim was to help explain this apparent paradox by evaluating endothelial function and urine albumin levels in MA and NHW...
  4. ncbi Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma
    Harrihar A Pershadsingh
    Department of Family Medicine, Kern Medical Center, Bakersfield, CA 93305, USA
    Int J Biochem Cell Biol 38:766-81. 2006
    ..The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value...
  5. ncbi Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient
    Harrihar A Pershadsingh
    Department of Family Medicine, Kern Medical Center, Bakersfield, CA 93305, and the Department of Family Medicine, University of California, Irvine, Irvine, CA, USA
    Skinmed 4:386-90. 2005
    ..7% to 7.2%) and liver function remained normal throughout the study (ALT, 24 IU/L; AST, 14 IU/L before treatment; and ALT, 26 IU/L; AST, 15 IU/L after treatment). There were no adverse events...
  6. ncbi Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand
    Melvin A Sarayba
    Department of Ophthalmology, University of California, 118 Med Surge I, Irvine, CA 92697 4375, USA
    Exp Eye Res 80:435-42. 2005
    ..To determine the efficacy of the peroxisome proliferator-activated receptor gamma agonist, pioglitazone, in inhibiting corneal neovascularization...
  7. ncbi Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone
    Nianning Qi
    Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    J Biol Chem 277:48501-7. 2002
    ..These findings provide direct pharmacogenetic evidence that in the SHR model, Cd36 is a key determinant of the insulin-sensitizing actions of a thiazolidinedione ligand of peroxisome proliferator-activated receptor gamma...
  8. ncbi Alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases
    Meenakshi S Venkatraman
    Department Medicinal Chemistry, University of Mississippi, University, MS, USA
    Arch Dermatol Res 296:97-104. 2004
    ..These findings suggest that water-soluble lipoic acid-based thiazolidinediones may be efficacious as oral and topical agents for treating inflammatory skin conditions such as contact dermatitis, atopic dermatitis, and psoriasis...
  9. ncbi Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
    James Varani
    University of Michigan Medical School, Department of Pathology, 1301 Catherine Road Box 0602, Ann Arbor, MI 48109, USA
    Expert Opin Investig Drugs 15:1453-68. 2006
    ..Other studies are aimed at identifying optimal ways to use these agents in the treatment of hyperplastic skin diseases such as psoriasis...
  10. ncbi Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists
    Amar G Chittiboyina
    Laboratory for Applied Drug Design and Synthesis, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, 38677, USA
    J Med Chem 49:4072-84. 2006
    ..These novel compounds may prove efficacious not only in the treatment of Type 2 diabetes, but also atherosclerosis, prevention of vascular restenosis, and inflammatory skin diseases...
  11. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  12. ncbi Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease
    Harrihar A Pershadsingh
    Diabetes Care 27:1015. 2004
  13. ncbi BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application
    Narasimharao Bhagavathula
    Department of Pathology, The University of Michigan, 1301 Catherine Rd, Box 0602, Ann Arbor, MI 48109, USA
    J Pharmacol Exp Ther 315:996-1004. 2005
    ..Concentrations of BP-1107 that effectively inhibit keratinocyte function have no detrimental effect on dermal fibroblasts. These data suggest that effective topical antipsoriatic therapy may be provided with this agent...
  14. ncbi Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes
    Narasimharao Bhagavathula
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    J Invest Dermatol 122:130-9. 2004
    ....
  15. ncbi Type 2 diabetes and oral antihyperglycemic drugs
    Cassia S Mizuno
    Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS 38677 1848, USA
    Curr Med Chem 15:61-74. 2008
    ..In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes...
  16. ncbi Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis
    Douglas L Feinstein
    Department of Anesthesiology, University of Illinois, 11819 West Polk Street, MC519, Chicago, IL 60612, USA
    Ann Neurol 51:694-702. 2002
    ..Pioglitazone also reduced the antigen-dependent interferon-gamma production from EAE-derived T cells. These results suggest that orally administered PPARgamma agonists could provide therapeutic benefit in demyelinating disease...